Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.
Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.
复制标题
DOI：
10.3390/vaccines10020160
复制
发表时间：
2022-01-21
期刊：
影响因子：
7.8
通讯作者：
Hung IF
中科院分区：
文献类型：
--
作者：
Khong KW;Liu D;Leung KY;Lu L;Lam HY;Chen L;Chan PC;Lam HM;Xie X;Zhang R;Fan Y;To KK;Chen H;Yuen KY;Chan KH;Hung IF
通过对已经接种过两剂COVID-19疫苗的个体接种SARS-CoV-2 naïve，我们旨在研究使用不同平台的疫苗作为加强剂的异源启动-增强策略是否可以增强对SARS-CoV-2病毒变体的免疫反应。参与者被分为四组，每组接受不同的疫苗接种组合：两剂BNT162b2后一剂BNT162b2增强剂（B-B-B）；BNT162b2（第一剂）和CoronaVac（第二剂）联合使用后，再加一剂BNT162b2增强剂（B-C-B）；两剂CoronaVac后加一剂CoronaVac增强剂（C-C-C）；两剂CoronaVac，随后一剂BNT162b2增强剂（C-C-B）。用活病毒微中和试验（vMN）测定血清中对病毒的中和抗体。B-B-B组和C-C-B组对SARS-CoV-2野生型（WT）、Beta变体（BV）和Delta变体（DV）的免疫原性显著提高。此外，B-B-B组和C-C-B组对Omicron变体（OV）的保护作用降低，但仍存在。此外，在增强剂量后3天观察到抗OV的vMN滴度持续上升。在安全性方面，异种的初强化疫苗策略耐受性良好。本研究表明，使用不同平台的疫苗作为加强剂可以增强对SARS-CoV-2变体的保护，对野生型病毒（WT）、Beta变体（BV）、Delta变体（DV）具有有效的中和活性，对Omicron变体（OV）具有一定的保护作用。此外，无论在哪个平台上使用初始剂量，增强mRNA疫苗都比灭活疫苗产生更强的免疫反应。
By vaccinating SARS-CoV-2 naïve individuals who have already received two doses of COVID-19 vaccines, we aimed to investigate whether a heterologous prime-boost strategy, using vaccines of different platforms as the booster dose, can enhance the immune response against SARS-CoV-2 virus variants. Participants were assigned into four groups, each receiving different combination of vaccinations: two doses of BNT162b2 followed by one dose of BNT162b2 booster (B-B-B); Combination of BNT162b2 (first dose) and CoronaVac (second dose) followed by one dose of BNT162b2 booster (B-C-B); two doses of CoronaVac followed by one dose of CoronaVac booster (C-C-C); two doses of CoronaVac followed by one dose of BNT162b2 booster (C-C-B). The neutralizing antibody in sera against the virus was determined with live virus microneutralization assay (vMN). The B-B-B group and C-C-B group demonstrated significantly higher immunogenicity against SARS-CoV-2 Wild type (WT), Beta variant (BV) and Delta variant (DV). In addition, the B-B-B group and C-C-B group showed reduced but existing protection against Omicron variant (OV). Moreover, A persistent rise in vMN titre against OV was observed 3 days after booster dose. Regarding safety, a heterologous prime-boost vaccine strategy is well tolerated. In this study, it was demonstrated that using vaccines of different platforms as booster dose can enhance protection against SARS-CoV-2 variants, offering potent neutralizing activity against wild-type virus (WT), Beta variant (BV), Delta variant (DV) and some protection against the Omicron variant (OV). In addition, a booster mRNA vaccine results in a more potent immune response than inactivated vaccine regardless of which platform was used for prime doses.
登录
查看更多内容
影响因子：
13.2
作者：
Ai J;Zhang H;Zhang Y;Lin K;Zhang Y;Wu J;Wan Y;Huang Y;Song J;Fu Z;Wang H;Guo J;Jiang N;Fan M;Zhou Y;Zhao Y;Zhang Q;Liu Q;Lv J;Li P;Qiu C;Zhang W
通讯作者：
Zhang W
DOI：
10.3390/diagnostics11101757
发表时间：
2021-09-24
期刊：
Diagnostics (Basel, Switzerland)
影响因子：
--
作者：
Chan KH;Leung KY;Zhang RR;Liu D;Fan Y;Chen H;Yuen KY;Hung IF
通讯作者：
Hung IF
影响因子：
12
作者：
Khan NA;Al-Thani H;El-Menyar A
通讯作者：
El-Menyar A
DOI：
10.1016/s1473-3099(20)30843-4
发表时间：
2021-03
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Zhang Y;Zeng G;Pan H;Li C;Hu Y;Chu K;Han W;Chen Z;Tang R;Yin W;Chen X;Hu Y;Liu X;Jiang C;Li J;Yang M;Song Y;Wang X;Gao Q;Zhu F
通讯作者：
Zhu F
DOI：
10.1016/s0140-6736(21)00241-5
发表时间：
2021-02-20
期刊：
Lancet (London, England)
影响因子：
--
作者：
Richmond P;Hatchuel L;Dong M;Ma B;Hu B;Smolenov I;Li P;Liang P;Han HH;Liang J;Clemens R
通讯作者：
Clemens R